Irisin protects against hind limb ischemia reperfusion injury

Küçük A., Polat Y., KILIÇARSLAN A. , SÜNGÜ N. , Kartal H., Dursun A. D. , ...More

Drug Design, Development and Therapy, vol.15, pp.361-368, 2021 (Journal Indexed in SCI Expanded) identifier identifier

  • Publication Type: Article / Article
  • Volume: 15
  • Publication Date: 2021
  • Doi Number: 10.2147/dddt.s279318
  • Title of Journal : Drug Design, Development and Therapy
  • Page Numbers: pp.361-368


© 2021 Küçük et al.Aim: The aim of this study was to evaluate the effects of irisin in a murine model of hind limb ischemia reperfusion (I/R). Methods: The mice were divided into four groups (n = 6 in each group): control, irisin, ischemia reperfusion (I/R), and irisin-ischemia reperfusion (I–I/R). Irisin (0.5 µg.g−1, intra-peritoneally [i.p.]) was administered 30 min before the I/R procedure. After 2 h of ischemia and 2.5 h of reperfusion, blood and tissue samples were taken for biochemical and histo-pathological analysis. The results were analyzed by Kruskal–Wallis and Mann–Whitney U-tests. Results: There was a statistically significant difference in the total antioxidant status (TAS) and total oxidant status (TOS) levels in all the groups. The TAS level in the I/R group was significantly lower than that in the control, irisin, and I–I/R groups, whereas the TOS level was significantly higher in the I/R group as compared with that in the other groups. Caspase-3 activity and caspase-8 activity, indicators of inflammation, were significantly higher in the I/R and I–I/R groups as compared with those in the control and irisin groups. Conclusion: Irisin may have protective effects in skeletal muscle ischemia reperfusion injury.